MedTrace Logo

Umbilical Cord Blood Mononuclear Cell Transplant to Treat Chronic Spinal Cord Injury

NCT01354483 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2014-08-21

No results posted yet for this study

Summary

The purpose of this study is to investigate the feasibility, safety, efficacy and optimal dose of umbilical cord blood mononuclear cell transplant in the treatment of chronic spinal cord injuries.

Conditions

  • Spinal Cord Injuries

Interventions

BIOLOGICAL

Umbilical Cord Blood Mononuclear Cell

BIOLOGICAL

Methylprednisolone

30mg/kg i.v. methylprednisolone

DRUG

Lithium Carbonate Tablet

6 weeks

Sponsors & Collaborators

  • Chengdu PLA General Hospital

    collaborator OTHER

  • China Spinal Cord Injury Network

    lead NETWORK

Principal Investigators

  • Hui Zhu, MD · Chengdu PLA General Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
FACTORIAL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-09-30
Primary Completion
2013-09-30
Completion
2013-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01354483 on ClinicalTrials.gov